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3Obesity is associated with increased risk of atherosclerotic vascular disease, including myocardial infarction (MI) 
and stroke,1,2 although the association between adiposity and 
stroke in older adults is uncertain.3–5 Adipose tissue, in addi-
tion to being a fat store, secretes a number of hormones such as 
adiponectin and leptin, which have been variably linked to the 
development of coronary heart disease6,7 and may be involved 
in the underlying biological mechanisms linking obesity to 
stroke. However, their role in stroke has been less studied. 
Although a number of cross-sectional and retrospective case–
control studies suggest that leptin and low adiponectin are asso-
ciated with increased stroke risk,8–13 prospective data on their 
association with stroke are limited and conflicting.8 Whereas 
1 prospective study suggested that leptin was a risk factor for 
stroke,14 2 recent prospective and nested case–control studies 
showed no association between leptin and stroke.15,16 Two pro-
spective nested case–control studies have reported an associa-
tion between low adiponectin and increased risk of stroke,16,17 
but other prospective studies have reported no association 
between adiponectin and stroke.14,15,18,19 We have examined the 
relationship between adiposity (body mass index [BMI], waist 
circumference [WC]) and the adipose-derived proteins leptin 
and adiponectin with risk of incident stroke in a prospective 
cohort of older men aged 60 to 79 years.
Subjects and Methods
The British Regional Heart Study is a prospective study of cardiovas-
cular disease (CVD) involving 7735 men, aged 40 to 59 years, drawn 
from general practice in each of 24 British towns, who were screened 
between 1978 and 1980.20 The population studied was socioeconomi-
cally representative of British men but comprised predominantly 
white Europeans (>99%). In 1998 to 2000, all surviving men, now 
aged 60 to 79 years (mean age, 68.7 years), were invited for a 20-year 
follow-up examination. The men completed a questionnaire that in-
cluded questions on their medical history and lifestyle behavior. They 
were requested to fast for a minimum of 6 hours, during which time 
they were instructed to drink only water and to attend for measure-
ment at a prespecified time between 0800 and 1800 hours. All men 
were asked to provide a blood sample, collected using the Sarstedt 
Monovette system. The samples were frozen and stored at −20°C on 
the day of collection and transferred in batches for storage at −70°C 
until analysis, performed after no more than 1 freeze-thaw cycle. 
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Twelve-lead ECGs were recorded using a Siemens Sicard 460 instru-
ment and were analyzed and coded in accordance with Minnesota 
Coding definitions at the University of Glasgow ECG core laboratory 
based at Glasgow Royal Infirmary.21 Atrial fibrillation was defined 
according to Minnesota codes 8.3.1 and 8.3.3. A total of 4252 men 
(77% of survivors) reported for examination. The men were asked 
whether a doctor had ever told them that they had angina or MI (heart 
attack, coronary thrombosis) or stroke, and to bring their medica-
tion to the examination session.  A total of 4094 men provided blood 
samples. We excluded men with a recall of a diagnosis of MI, stroke, 
or heart failure (n=678), and we excluded 5 additional men with no 
adiposity measures, leaving 3411 men for analysis.
Cardiovascular Risk Factors
Anthropometric measurements including body weight, height, and 
WC were performed. Details of measurements and classification 
methods for smoking status, physical activity, BMI, WC, social class, 
forced expiratory volume in 1 second, blood pressure, renal dysfunc-
tion, and lipids have been described.22–25 Men with a doctor’s diagno-
sis of diabetes mellitus or those with a fasting glucose of >7 mmol/L 
(World Health Organization criteria) were considered to have preva-
lent diabetes mellitus.
Hemostatic and Inflammatory Biomarkers
At the 20-year examination, D-dimer was measured with ELISA 
(Biopool AB), as was von Willebrand factor (VWF) antigen (DAKO). 
C-reactive protein (CRP) was assayed by ultrasensitive nephelometry 
(Dade Behring). Interleukin-6 (IL-6) was assayed using a high-sensi-
tivity ELISA (R&D Systems).
Adiponectin and Leptin
Plasma adiponectin concentrations were determined using ELISA 
(R&D Systems). The intra-assay and the interassay coefficients of 
variability were each 7.5%. We previously have shown this method 
to correlate well with a radioimmunoassay method for adiponectin 
measurement.6 Plasma leptin was measured by an in-house radioim-
munoassay carefully validated against the commercially available 
Linco assay, as previously described.7 The intra-assay and interas-
say coefficients of variation were <7% and <10%, respectively, over 
the sample concentration range. The detection limit of the assay was 
0.5 ng/mL, which is superior to commercial assays. Within-person 
variation of leptin values over 4 years was high (correlation coeffi-
cient, 0.79; 95% confidence interval, 0.73–0.83,7 and for adiponectin 
the correlation coefficient was 0.58 and 95% confidence interval was 
0.49–0.66.6 Data on adiponectin were available for 3372 men and 
were available for leptin for 3218 men. Men with missing data were 
excluded from analysis.
Follow-up
All men had been followed-up from initial examination (1978–1980) 
for cardiovascular morbidity and follow-up had been achieved for 
99% of the cohort.26 In the present analyses, all-cause mortality and 
morbidity events were based on follow-up from rescreening in 1998 
to 2000 at mean age of 60 to 79 years to July 2008, which is a mean 
follow-up period of 9 years (range, 8–10 years). Information on death 
was collected through the established tagging procedures provided 
by the National Health Service registers. Fatal stroke episodes were 
those coded on the death certificate as International Classification of 
Diseases 430–438. Nonfatal stroke events were those that produced 
a neurological deficit that was present for >24 hours. Evidence re-
garding nonfatal stroke was obtained by ongoing reports from gen-
eral practitioners, by biennial reviews of the patients’ practice records 
(including hospital and clinic correspondence) through to the end of 
the study period, and from repeated personal questionnaires to sur-
viving subjects after initial examination. Supplementary information 
on computerized tomography/MRI scans were only available for 
100 (52%) of the 192 stroke cases. Of these, 62 (62%) were isch-
emic stroke, 9 (0.9%) were hemorrhagic strokes, and 29 (29%) were 
indeterminate.
Statistical Methods
The distribution of leptin and adiponectin was skewed and log trans-
formation was used. Cox proportional hazards model was used 
to assess the multivariate-adjusted hazards ratio (relative risk) in a 
comparison of quartiles of leptin and adiponectin. To assess the as-
sociation between BMI and stroke, we considered BMI as a categori-
cal variable based on World Health Organization cut-offs (normal 
weight, BMI 18.5–24.9 kg/m2; overweight, BMI 25.0–29.9 kg/m2; 
and obese, BMI >30 kg/m2). Similarly we considered WC as a cat-
egorical variable using 3 categories: <94 cm; 94 to 101 cm; and >102 
cm. In multivariate analyses, smoking (never, long-term ex-smokers 
[>15 years], recent ex-smokers [<15 years], and current smokers), 
social class (manual vs nonmanual), physical activity (4 groups), al-
cohol intake (5 groups), diabetes mellitus (yes or no), and angina (yes 
or no) were fitted as categorical variables; forced expiratory volume 
in 1 second, CRP, IL-6, vWF, γ-glutamyl transferase, and D-dimer 
were fitted as continuous variables. P<0.05 was used for statistical 
significance.
Results
During the mean follow-up period of 9 years, there were 192 
incident stroke cases (5.9/1000 person-years) in the 3411 men 
with no history of stroke, MI, or heart failure. Table 1 shows 
baseline characteristics in the men who had development of 
stroke and in those who remained free of stroke. Men who had 
development of stroke showed higher rates of blood pressure 
treatment and higher mean levels of systolic and diastolic 
blood pressure, CRP, and IL-6, and lower levels of forced 
expiratory volume in 1 second. Leptin levels were higher in 
stroke cases (P=0.07). Little difference was seen between 
stroke and adiponectin levels (P=0.55).
There was no significant association between measures of adi-
posity (WC or BMI) and risk of stroke (Table 2) in  age-adjusted 
analysis. Adjustment for potential confounders including blood 
pressure reduced the risk in obese men further, and the lower 
risk in obese men compared with those with BMI <25 kg/m2 
was significant (P=0.04). Exclusion of men with renal dys-
function (estimated glomerular filtration rate <60 mL/min 
per 1.73 m2) or history of cancer did not alter the findings.
Leptin was associated with many risk factors, including 
blood pressure, γ-glutamyl transferase, markers of inflam-
mation (CRP and IL-6), vWF, and D-dimer, although the 
association with blood pressure was abolished after adjust-
ment for age and BMI (Table 3). Adiponectin showed lit-
tle association with blood pressure and the associations 
with markers of inflammation, γ-glutamyl transferase, and 
vWF were attenuated after adjustment for age and BMI. 
Increased leptin was associated with significantly increased 
risk of stroke after adjustment for age and BMI (Table 4). 
Adjustment for potential confounders and blood pressure 
caused minor differences in the association. Further adjust-
ment for CRP, vWF, γ-glutamyl transferase, and D-dimer 
attenuated the association but risk remained significantly 
increased in those with increased leptin. Adjusting for IL-6 
instead of CRP yielded similar results. By contrast, no con-
sistent association was seen between adiponectin and risk 
of stroke.
We also conducted a sensitivity analysis restricting incident 
cases to confirmed ischemic strokes (n=62 cases). Elevated 
leptin was significantly associated with ischemic stroke 
after adjustment for factors in model 1 in Table 4 (adjusted 
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hazard ratio, quartile 4 vs quartile 1 2.31; confidence interval, 
1.03–5.17).
Discussion
In this large population study of British men aged 60 to 79 
years, increased adiposity was not associated with increased 
stroke incidence. WC showed no association with stroke risk 
at all; however obese men (BMI >30 kg/m2) tended to have the 
lowest risk, in contrast to the leptin results. However, we have 
confirmed the findings of some previous prospective studies 
that leptin,14 but not adiponectin,14,15,18,19 is associated with 
incident stroke after adjusting for BMI and established risk 
factors for stroke. Our findings extend those of other studies 
on adipocytes and risk of stroke by examining the associa-
tion in a population at high risk for stroke and by assessing a 
wide range of potential mediators and mechanisms, including 
inflammation, metabolic risk factors, endothelial dysfunction 
(vWF), and fibrinolytic factors (D-dimer).
Despite leptin being a strong correlate of adiposity, BMI and 
WC were not associated with increased risk of stroke in older 
men in age-adjusted analyses. Our null findings are consistent 
with 2 other population studies that have shown no association 
between adiposity and stroke in older men.4,5 The lack of posi-
tive association between WC and BMI and stroke, in contrast 
to the positive association of leptin, may reflect the weaker 
associations between WC, BMI, and the true percentage of 
adipose tissue in older people. Alternatively, the paradoxical 
finding of a null relationship between WC and CVD risk and 
an inverse association between BMI and CVD seen even after 
exclusion of men with preexisting cancer and low renal func-
tion may reflect what is often seen in those with established 
CVD, commonly referred to as the obesity paradox.27 Although 
men with established CVD and stroke were excluded, it is pos-
sible that many of these older men have subclinical CVD or 
pulmonary disease conditions in which the obesity paradox is 
often reported. Thus, subclinical disease in a proportion of men 
is likely leading to weight loss, particularly lean body mass, 
and so these men have low current BMI, whereas fat mass (and 
therefore leptin concentration) is less affected.
A significant positive association was observed between 
increased leptin and stroke in these older men independent 
of BMI and established stroke risk factors, including smok-
ing and systolic blood pressure. Leptin exerts many poten-
tially atherogenic effects, such as induction of endothelial 
Table 1. Baseline Characteristics (1998–2000) in 3411 Men Without Preexisting Myocardial Infarction, Stroke, or Heart Failure 
According to Incident Stroke Status
No Stroke (n=3219) Developed Stroke (n=192) P Difference
Age, y 68.24 (5.40) 71.16 (5.38) <0.0001
BMI, kg/m2 26.80 (3.59) 26.58 (3.45) 0.42
WC, cm 96.84 (10.2) 96.87 (10.0) 0.97
Inactive, % 31.8 38.2 0.07
Current smokers, % 5.6 6.3 0.59
Manual, % 53.2 56.1 0.50
Moderate/heavy drinkers, % 19.2 21.1 0.53
Using blood pressure treatment, % 5.3 7.3 0.04
Angina, % 5.6 7.0 0.31
Diabetes mellitus, % 5.7 5.9 0.89
Atrial fibrillation, % 2.8 4.2 0.29
SBP, mm Hg 149.4 (23.7) 157.1 (25.3) <0.0001
DBP, mm Hg 85.51 (10.9) 87.35 (12.3) 0.02
Cholesterol, mmol/L 6.05 (1.06) 6.09 (1.16) 0.63
HDL cholesterol, mmol/L 1.33 (0.34) 1.33 (0.36) 0.91
FEV1, L 2.64 (0.65) 2.45 (0.66) 0.0002
Glucose, mmol/L* 5.81 (5.25–6.08) 5.93 (5.23–6.16) 0.30
HOMA-IR 0.78 (0.33–1.14) 0.83 (0.34–1.08) 0.35
GGT, U/L 28.22 (19–38) 30.87 (19–46) 0.04
CRP, mg/L* 1.63 (0.78–3.21) 2.11 (1.05–3.90) 0.002
IL-6, pg/mL* 2.34 (1.52–3.31) 2.94 (1.77–4.25) <0.0001
vWF, IU/dL 136.8 (45.1) 150.2 (50.1) <0.0001
D-dimer, ng/mL* 79.0 (47–117) 102.5 (60.5–156.5) <0.0001
Adiponectin, µg/mL* 6.75 (4.36–10.84) 7.03 (4.29–10.71) 0.55
Leptin, ng/mL* 8.93 (5.6–13.9) 9.87 (6.0–16.4) 0.07
BMI indicates body mass index; CRP, C-reactive protein; DBP, diastolic blood pressure; FEV1, forced expiratory volume in 1 second; GGT, γ-glutamyl transferase; HDL, 
high-density lipoprotein; HOMA-IR, homeostasis model of assessment of insulin resistance; IL, interleukin; SBP, systolic blood pressure; SD, standard deviation; vWF, 
von Willebrand factor. WC, waist circumference. Data are mean (SD) unless specified.
*Geometric mean and interquartile range.
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dysfunction, stimulation of inflammatory reaction, and influ-
ence on coagulation/fibrinolysis balance,28,29 which may 
contribute to stroke development. However, the association 
between leptin and stroke was not explained by inflammation 
(CRP or IL-6), vWF (a marker of endothelial dysfunction), or 
D-dimer (marker of fibrinolytic activity).
Other potential mechanisms by which leptin may contrib-
ute to stroke risk may be through its direct proatherogenic 
effect on oxidative stress, platelet aggregation, and prolif-
eration of vascular smooth muscle cells, which play a vital 
role in arterial intima thickening.28,29 In population studies, 
hyperleptinemia has been associated with increased intima-
media thickness of the common carotid artery,30 which has 
been more strongly linked to incident stroke than to MI.31 
This would be consistent with the finding that leptin predicted 
incident stroke but has not been shown to be associated with 
coronary heart disease in this study.25 Thus, leptin may have 
a direct atherogenic effect on the carotid artery wall, which 
may be the pathway by which leptin contributes to develop-
ment of stroke.
Of course, it is possible that leptin, being a strong correlate 
to percent fat mass,32 is better at identifying older men with 
more total fat load (and, by association, less muscle mass). 
Thus leptin, rather than exerting a direct toxic effect, may 
signal changes in body morphology not available via conven-
tional adiposity measures but that are linked to stroke risk. 
This hypothesis is speculative and requires future study.
Our study is not without some limitations. It was based 
on an older, predominantly white male population, so that 
the results cannot be generalized directly to women, younger 
men, or other ethnic groups. In a recent report in women and 
in middle-aged men, leptin was not shown to be associated 
Table 2. Incidence Rates Per 1000 Person-Years and Adjusted Relative Hazard Ratios and 95% Confidence Intervals for Incident 
Stroke in Men by Levels of Body Mass Index and Waist Circumference in Those With No Preexisting Stroke, Myocardial Infarction, 
or Heart Failure
BMI, kg/m2
<25.0 25.0–29.9 >30.0 P Trend Across the Groups
N of men (cases) 1067 (67) 1797 (103) 540 (21)
Rate/1000 person-years 7.9 7.0 5.0
Age-adjusted HR 1.00 0.94 (0.69–1.28) 0.69 (0.42–1.13) 0.19
Model 1 1.00 0.88 (0.64–1.21) 0.60 (0.36–0.98)* 0.07
WC, cm P Trend Across the Groups
<94 94–102 >102
N of men (cases) 1324 (74) 1122 (68) 951 (50)
Rate/1000 person-years 6.8 7.3 6.6
Age-adjusted HR 1.00 1.12 (0.81–1.55) 1.00 (0.70–1.43) 0.95
Model 1 1.00 1.04 (0.75–1.46) 0.85 (0.58–1.24) 0.50
BMI indicates body mass index; HR, hazard ratio.
Model 1: adjusted for age, diabetes mellitus, angina, atrial fibrillation, smoking, social class, alcohol intake, physical activity, lung function, systolic blood pressure, 
and use of antihypertensive drugs.
*Test difference between BMI >30 vs <25.0 group. P=0.04.
Table 3. Correlation Coefficients Relating Leptin and Adiponectin to Biological Cardiovascular Risk Factors
Leptin Adiponectin
Unadjusted Age- and BMI-Adjusted  Unadjusted Age- and BMI-Adjusted
Age 0.02 0.16
BMI 0.57* −0.15
WC 0.57* −0.16
Adiponectin −0.09* −0.004
Systolic blood pressure 0.06† 0.01 0.03 0.02
Diastolic blood pressure 0.06† 0.01 0.03 0.05†
FEV1 −0.08* −0.09* −0.07* −0.02
GGT 0.20* 0.11* −0.08* −0.03
CRP 0.21* 0.12* −0.06* −0.06†
IL-6 0.14* 0.07* −0.01 −0.03
vWF 0.13* 0.14* 0.04‡ 0.01
d-dimer 0.08† 0.07† 0.02 −0.03
BMI indicates body mass index; CRP, C-reactive protein; FEV1, forced expiratory volume in 1 second; GGT, γ-glutamyl transferase; IL, interleukin; vWF, von Willebrand 
factor; WC, waist circumference.
*P<0.0001; †P<0.01; ‡P<0.05
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with incident stroke.15,17 Leptin levels vary by gender in 
keeping with greater fat mass in women, and it is possible 
that there are possible interactions between gender, leptin, 
and incident stroke that we were not able to explore in this 
study of men only. Leptin and adiponectin levels in this older 
population were comparable with other studies.16,17 The find-
ings were based on a single measurement at the baseline 
re-examination. However, both leptin and adiponectin are 
reasonably stable over time in individuals, as reflected by the 
within-individual consistency over a 4-year period for leptin 
(r=0.79) and adiponectin (r=0.58).6,7 This may have led to 
some underestimation of the true strength of the association 
between leptin and stroke but is unlikely to effect the null 
association between adiponectin and stroke. The study popu-
lation is socially representative of the United Kingdom, and 
follow-up rates in the British Regional Heart Study are excep-
tionally high. Although ascertainment of strokes in this study 
is based on general practice medical records of the men, our 
incidence rates of 6.9/1000 person-years correspond closely 
with those of the Oxfordshire Vascular Study (6.8/1000 per 
year) and the Scottish Borders Stroke Study (6.6/1000 per 
year).33 Information on type of stroke was not routinely avail-
able in all stroke cases, although most stroke cases (85%) in 
the United Kingdom are because of ischemia.34 In a sensitiv-
ity analysis based on confirmed ischemic stroke cases, find-
ings were similar to those for the whole study population, 
confirming an association with ischemic stroke. The number 
of confirmed hemorrhagic stroke in this study was too small 
to examine separately, but previous reports have observed 
an association between leptin and both ischemic and hemor-
rhagic stroke.14,35
In conclusion, we have shown that BMI and WC are 
not associated with increased risk of stroke in older men. 
However, the adipose tissue-derived hormone leptin, but not 
adiponectin, predicted stroke in older men, independent of 
established risk factors for stroke and markers of inflamma-
tion (CRP IL-6), endothelial dysfunction (vWF), and fibrino-
lytic factors (D-dimer). Whether our observation represents a 
direct or indirect link between leptin and stroke risk requires 
future study.
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